-

2
100

75

52%

-Cell
function
(%)

50
Insulin
resistance

IGT
Postprandial
Hyperglycemia

0
-12

-10

-6

Type 2 Diabetes
Phase III

Type 2
Diabetes
Phase I

25

-2

Type 2
Diabetes
Phase II

Diagnosis
Years from diagnosis

10

14

ukpds

Dashed line shows extrapolation forward and backward from years 0 to 6 based on HOMA data from UKPDS.
Lebovitz H. Diabetes Rev 1999;7:139153.
Holman RR. Diabetes Res Clin Pract 1998;40(suppl):S21-S25.


Statement ADA & EASD 2006

+ Metformin

+ +/-
Diabetes Care 2006; 29 :1963 -72


Position Statement ADA EASD 2012

Diabetologia 2012


2013



...

!

Many years ago, Elliot Joslin said:

'Insulin is a treatment for the wise
and not for the foolish,
whether they be patients or doctors.'


GLP-1


GLP-1

J. Meier Nat. Rev. Endocrinol. 2012;8:728-742

H GLP-1-R

J. Meier Nat. Rev. Endocrinol. 2012;8:728-742


GLP-1

A . Flint et al Adv Ther. 2011;28:21326.

KB. Degn et al Diabetes2004;53:118794.

 GLP-1

GLP-1**

FPG

PPG

* glargine

** 10 g

JB Buse et al.,. Ann Intern ed. 2011, 154:103-112

20

FPG

PPG

A1C. A1C 1,74%

1,04% ( -0,69%, P <0,001)

-
Position Statement ADA EASD 2012

Diabetes Care 2012:35;1364-1380

Diabetologia 2012:55;1577-1597

. J. Abrahanson et al Endocrine Practise 2013;19:327-337


2: ;

: .

2
.

GLP-1

.